Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Apr 13, 2006
Letter to Shareholders of Hemispherx Biopharma, Inc. from William A. Carter, M.D., Chairman of the Board and Chief Executive Officer
Apr 11, 2006
HEMISPHERX BIOPHARMA TO HOST CONFERENCE CALL TO REVIEW COMPANY'S ACCOMPLISHMENTS, UPDATE ON INFLUENZA RELATED STUDIES AND OUTLINE FUTURE GOALS
Apr 07, 2006
Hemispherx Biopharma, Inc. Late Filing of Form 10-K Generates Standard Non-Compliance Notification From The AMEX
Apr 03, 2006
Hemispherx Biopharma, Inc. Announces Delay in Filing Its Form 10-K for the Fiscal Year Ended December 31, 2005
Mar 16, 2006
New Research From Hemispherx Biopharma Leverages Recent Studies to Identify Factors in Breakdown of Immune System; May Help Prevent Spread of Avian Flu
Feb 16, 2006
3 New Studies Show Hemispherx Biopharma's Ampligen® and Alferon® LDO May Provide Defense Against Avian Flu
Jan 03, 2006
HEMISPHERX BIOPHARMA LETTER TO SHAREHOLDERS
Dec 20, 2005
Hemispherx to Present at the 4th Annual Biodefense Research Meeting Sponsored by the American Society of Microbiology, Ampligen® and Alferon® in Global Clinical / Animal Trials Against Avian Influenza
Dec 13, 2005
Hemispherx Highlighted in Study of Innate Immunity As a Defense Against Bio-terror Threats,
Dec 12, 2005
HEMISPHERX BIOPHARMA TO PRESENT AT THE NEW YORK SOCIETY OF SECURITY ANALYSTS 9TH ANNUAL HEALTHCARE INDUSTRY CONFERENCE
54
55
56
57
58
59
60
61
62
63
64
<<
<
>
>>
Privacy